Advertisement

Diabetologia

, Volume 61, Issue 1, pp 101–107 | Cite as

Glucose patterns during an oral glucose tolerance test and associations with future diabetes, cardiovascular disease and all-cause mortality rate

  • Adam Hulman
  • Dorte Vistisen
  • Charlotte Glümer
  • Michael Bergman
  • Daniel R. Witte
  • Kristine Færch
Short Communication

Abstract

Aims/hypothesis

In addition to blood glucose concentrations measured in the fasting state and 2 h after an OGTT, intermediate measures during an OGTT may provide additional information regarding a person’s risk of future diabetes and cardiovascular disease (CVD). First, we aimed to characterise heterogeneity of glycaemic patterns based on three time points during an OGTT. Second, we compared the incidences of diabetes and CVD and all-cause mortality rates among those with different patterns.

Methods

Our cohort study included 5861 participants without diabetes at baseline from the Danish Inter99 study. At baseline, all participants underwent an OGTT with measurements of plasma glucose levels at 0, 30 and 120 min. Latent class mixed-effects models were fitted to identify distinct patterns of glycaemic response during the OGTT. Information regarding incident diabetes, CVD and all-cause mortality rates during a median follow-up time of 11, 12 and 13 years, respectively, was extracted from national registers. Cox proportional hazard models with adjustment for several cardiometabolic risk factors were used to compare the risk of diabetes, CVD and all-cause mortality among individuals in the different latent classes.

Results

Four distinct glucose patterns during the OGTT were identified. One pattern was characterised by high 30 min but low 2 h glucose values. Participants with this pattern had an increased risk of developing diabetes compared with participants with lower 30 min and 2 h glucose levels (HR 4.1 [95% CI 2.2, 7.6]) and participants with higher 2 h but lower 30 min glucose levels (HR 1.5 [95% CI 1.0, 2.2]). Furthermore, the all-cause mortality rate differed between the groups with significantly higher rates in the two groups with elevated 30 min glucose. Only small non-significant differences in risk of future CVD were observed across latent classes after confounder adjustment.

Conclusions/interpretation

Elevated 30 min glucose is associated with increased risk of diabetes and all-cause mortality rate independent of fasting and 2 h glucose levels. Therefore, subgroups at high risk may not be revealed when considering only fasting and 2 h glucose levels during an OGTT.

Keywords

30 minute post-OGTT glucose Cardiovascular disease Latent class modelling Mortality Oral glucose tolerance test Plasma glucose curve Type 2 diabetes 

Abbreviations

1hPG

1 h plasma glucose

2hPG

2 h plasma glucose

30minPG

30 min plasma glucose

CVD

Cardiovascular disease

FPG

Fasting plasma glucose

ISI0–120

Insulin sensitivity index

PG-AUC

Area under the plasma glucose curve

PG-iAUC

Incremental area under the plasma glucose curve

Notes

Acknowledgements

AH and DRW are supported by the Danish Diabetes Academy. The Danish Diabetes Academy is funded by the Novo Nordisk Foundation. KF is supported by the Novo Nordisk Foundation.

Data availability

The raw data underlying this study are restricted to protect participant privacy as required by data protection acts in Denmark. Data will be made available upon request to researchers who qualify for access to confidential data by contacting The Research Centre for Prevention and Health, the Capital Region of Denmark, Email: fcfs@regionh.dk.

Funding

The Inter99 study was funded by the Danish Research Councils, Health Foundation, Danish Centre for Evaluation and Health Technology Assessment, Copenhagen County, Danish Heart Foundation, Ministry of Health and Prevention, Association of Danish Pharmacies, Augustinus Foundation, Novo Nordisk, Velux Foundation, Becket Foundation, and Ib Henriksens Foundation. The sponsors were not involved in the design of the study; the collection, analysis and interpretation of data; writing the report; or the decision to submit the report for publication.

Duality of interest

The authors declare that there is no duality of interest associated with this manuscript.

Contribution statement

AH was responsible for the data analysis with major contributions from DV. AH wrote the first draft of the manuscript with major contributions from KF. AH, DRW, KF and MB contributed to the original idea for the study. All authors contributed to the interpretation of the data, drafting and critical revision of the manuscript, and approved the final version. AH is the guarantor of this work.

Supplementary material

125_2017_4468_MOESM1_ESM.pdf (388 kb)
ESM Methods (PDF 387 kb)

References

  1. 1.
    World Health Organization (2006) Definition and diagnosis of diabetes mellitus and intermediate hyperglycemia: report of a WHO/IDF Consultation. Available from www.who.int/diabetes/publications/Definition%20and%20diagnosis%20of%20diabetes_new.pdf. Accessed 21 Sep 2017
  2. 2.
    Abdul-Ghani MA, Williams K, DeFronzo RA, Stern M (2007) What is the best predictor of future type 2 diabetes? Diabetes Care 30:1544–1548CrossRefPubMedGoogle Scholar
  3. 3.
    Alyass A, Almgren P, Akerlund M et al (2015) Modelling of OGTT curve identifies 1 h plasma glucose level as a strong predictor of incident type 2 diabetes: results from two prospective cohorts. Diabetologia 58:87–97CrossRefPubMedGoogle Scholar
  4. 4.
    Jagannathan R, Sevick MA, Li H et al (2016) Elevated 1-hour plasma glucose levels are associated with dysglycemia, impaired beta-cell function, and insulin sensitivity: a pilot study from a real world health care setting. Endocrine 52:172–175CrossRefPubMedGoogle Scholar
  5. 5.
    Bergman M, Chetrit A, Roth J, Dankner R (2015) Dysglycemia and long-term mortality: observations from the Israel study of glucose intolerance, obesity and hypertension. Diabetes Metab Res Rev 31:368–375CrossRefPubMedGoogle Scholar
  6. 6.
    Abdul-Ghani MA, Lyssenko V, Tuomi T, Defronzo RA, Groop L (2010) The shape of plasma glucose concentration curve during OGTT predicts future risk of type 2 diabetes. Diabetes Metab Res Rev 26:280–286CrossRefPubMedGoogle Scholar
  7. 7.
    Kanauchi M, Kimura K, Kanauchi K, Saito Y (2005) Beta-cell function and insulin sensitivity contribute to the shape of plasma glucose curve during an oral glucose tolerance test in non-diabetic individuals. Int J Clin Pract 59:427–432CrossRefPubMedGoogle Scholar
  8. 8.
    Lind M, Tuomilehto J, Uusitupa M et al (2014) The association between HbA1c, fasting glucose, 1-hour glucose and 2-hour glucose during an oral glucose tolerance test and cardiovascular disease in individuals with elevated risk for diabetes. PLoS One 9:e109506CrossRefPubMedPubMedCentralGoogle Scholar
  9. 9.
    Bergman M, Chetrit A, Roth J, Dankner R (2016) One-hour post-load plasma glucose level during the OGTT predicts mortality: observations from the Israel Study of Glucose Intolerance, Obesity and Hypertension. Diabet Med 33:1060–1066CrossRefPubMedGoogle Scholar
  10. 10.
    Hulman A, Simmons RK, Vistisen D et al (2017) Heterogeneity in glucose response curves during an oral glucose tolerance test and associated cardiometabolic risk. Endocrine 55:427–434CrossRefPubMedGoogle Scholar
  11. 11.
    Hulman A, Gujral UP, Narayan KMV et al (2017) Glucose patterns during the OGTT and risk of future diabetes in an urban Indian population: the CARRS study. Diabetes Res Clin Pract 126:192–197CrossRefPubMedGoogle Scholar
  12. 12.
    Jorgensen T, Borch-Johnsen K, Thomsen TF, Ibsen H, Glumer C, Pisinger C (2003) A randomized non-pharmacological intervention study for prevention of ischaemic heart disease: baseline results Inter99. Eur J Cardiovasc Prev Rehabil 10:377–386CrossRefPubMedGoogle Scholar
  13. 13.
    Cederholm J, Wibell L (1990) Insulin release and peripheral sensitivity at the oral glucose tolerance test. Diabetes Res Clin Pract 10:167–175CrossRefPubMedGoogle Scholar
  14. 14.
    Gutt M, Davis CL, Spitzer SB et al Validation of the insulin sensitivity index0, 120: comparison with other measures. Diabetes Res Clin Pract 47:177–184Google Scholar
  15. 15.
    Seltzer HS, Allen EW, Herron AL Jr, Brennan MT (1967) Insulin secretion in response to glycemic stimulus: relation of delayed initial release to carbohydrate intolerance in mild diabetes mellitus. J Clin Invest 46:323–335CrossRefPubMedPubMedCentralGoogle Scholar
  16. 16.
    Carstensen B, Kristensen JK, Marcussen MM, Borch-Johnsen K (2011) The National Diabetes Register. Scand J Public Health 39:58–61CrossRefPubMedGoogle Scholar
  17. 17.
    Helweg-Larsen K (2011) The Danish Register of causes of death. Scand J Public Health 39:26–29CrossRefPubMedGoogle Scholar
  18. 18.
    Lynge E, Sandegaard JL, Rebolj M (2011) The Danish National Patient Register. Scand J Public Health 39:30–33CrossRefPubMedGoogle Scholar
  19. 19.
    Rutter MK, Meigs JB, Sullivan LM, D’Agostino RB Sr, Wilson PW (2005) Insulin resistance, the metabolic syndrome, and incident cardiovascular events in the Framingham Offspring Study. Diabetes 54:3252–3257CrossRefPubMedGoogle Scholar
  20. 20.
    Zethelius B, Cederholm J (2015) Comparison between indexes of insulin resistance for risk prediction of cardiovascular diseases or development of diabetes. Diabetes Res Clin Pract 110:183–192CrossRefPubMedGoogle Scholar
  21. 21.
    Soulimane S, Simon D, Herman WH et al (2014) HbA1c, fasting and 2 h plasma glucose in current, ex- and never-smokers: a meta-analysis. Diabetologia 57:30–39CrossRefPubMedGoogle Scholar

Copyright information

© Springer-Verlag GmbH Germany 2017

Authors and Affiliations

  • Adam Hulman
    • 1
    • 2
    • 3
  • Dorte Vistisen
    • 4
  • Charlotte Glümer
    • 5
  • Michael Bergman
    • 6
  • Daniel R. Witte
    • 1
    • 2
  • Kristine Færch
    • 4
  1. 1.Department of Public HealthAarhus UniversityAarhus CDenmark
  2. 2.Danish Diabetes AcademyOdenseDenmark
  3. 3.Department of Medical Physics and InformaticsUniversity of SzegedSzegedHungary
  4. 4.Steno Diabetes Center CopenhagenGentofteDenmark
  5. 5.Research Centre for Prevention and HealthGlostrup HospitalGlostrupDenmark
  6. 6.Division of Endocrinology, Diabetes and MetabolismNYU School of Medicine, NYU Langone Diabetes Prevention ProgramNew YorkUSA

Personalised recommendations